ruxolitinib

Drug #2341

ruxolitinib blocks certain enzymes in the body that affect blod cell production,to treat myelofibrosis or polycythemia vera which are bone marrow disorders that affect body`s ability to produce cells

← Previous drug Next drug →

Primary Characteristics

It belongs to Kinase Inhibitor.

Molecular Weight: 306.37 · Non-proprietary name: ruxolitinib.

Pharmacokinetics

Distribution: ruxolitinib has a volume of distribution is 72 L. plasma protein binding is 97%.

Elimination: plasma half-life is 5.8 hours., renal excretion is 18.7 L/h..

Indications

ruxolitinib is primarily indicated in conditions like Myelofibrosis, Polycythemia vera.

Contraindications

None recorded.

Dosage

None recorded.

Drug Interactions

None recorded.

Side Effects

The signs and symptoms that are produced after acute overdosage of ruxolitinib are Vomiting, Dizziness, Headache, Thrombocytopenia , Vertigo , Neutropenia .

Warnings / Precautions

Treatment with Jakafi can cause thrombocytopenia, anemia and neutropenia. Serious bacterial, mycobacterial, fungal and viral infections have occurred. Delay starting therapy with Jakafi until active serious infections have resolved. Observe patients receiving Jakafi for signs and symptoms of infection and manage promptly. Progressive multifocal leukoencephalopathy (PML) has occurred with ruxolitinib treatment for myelofibrosis. If PML is suspected, stop Jakafi and evaluate. Advise patients about early signs and symptoms of herpes zoster and to seek treatment as early as possible. Following discontinuation of Jakafi, symptoms from myeloproliferative neoplasms may return to pretreatment levels over a period of approximately one week

Available Brands

None recorded.